Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alefacept - Astellas Pharma

Drug Profile

Alefacept - Astellas Pharma

Alternative Names: Amevive; ASP 0485; BG 9273; BG 9712; Human LFA-3/IgG fusion protein; LFA 3 TIP; Recombinant LFA-3/IgG1 human fusion protein

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Michigan Medical School
  • Developer Astellas Pharma; Cleveland Clinic
  • Class Antipsoriatics; Recombinant fusion proteins
  • Mechanism of Action CD2 antigen inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Psoriasis
  • Phase I/II Aplastic anaemia
  • Discontinued Psoriatic arthritis; Transplant rejection

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 24 Jan 2018 Astellas Pharma terminates a phase I/II trial due to the study drug not available at the time in Aplastic anaemia (Treatment-experienced) in USA (IV) (NCT01267643)
  • 15 Mar 2012 Astellas Pharma completes its Phase-II trial for Psoriasis in USA, Bulgaria and Latvia (NCT00808223)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top